Patents Assigned to Ecole Nationale Veterinaire d'Alfort
-
Patent number: 11530452Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: GrantFiled: September 3, 2020Date of Patent: December 20, 2022Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
-
Patent number: 11103564Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.Type: GrantFiled: June 19, 2019Date of Patent: August 31, 2021Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Luis G. Bermudez-Humaran, Thibault Allain, Isabelle Florent, Philippe Langella, Philippe Grellier, Marie-Agnes Travers, Bruno Polack
-
Publication number: 20210077759Abstract: Liquid ventilator and methods integrating the concept of total liquid ventilation (TLV) using liquid volumes below functional residual capacity (FRC) of mammal's lungs are disclosed. Beyond the automatization of the whole process, the technology has been up-scaled to confirm that TLV at residual volumes below FRC can provide a safe procedure while enabling the full potential of TLV in a mammal such as humans or adult-sized animals. Such tidal liquid ventilation strongly differs from the previously known TLV approach, opening promising perspectives for a safer clinical translation. Also disclosed are apparatus and method for safe and fast induction of hypothermia during liquid ventilation of a mammal.Type: ApplicationFiled: April 12, 2019Publication date: March 18, 2021Applicants: UNIVERSITE DE SHERBROOKE, ECOLE NATIONALE VETERINAIRE D'ALFORT, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Philippe MICHEAU, Renaud TISSIER, Matthias KOHLHAUER, Julien MOUSSEAU, Mathieu NADEAU, Jonathan VANDAMME
-
Patent number: 10808284Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: GrantFiled: July 7, 2015Date of Patent: October 20, 2020Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
-
Patent number: 10328132Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.Type: GrantFiled: August 10, 2015Date of Patent: June 25, 2019Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Luis G. Bermudez-Humaran, Thibault Allain, Isabelle Florent, Philippe Langella, Philippe Grellier, Marie-Agnes Travers, Bruno Polack
-
Patent number: 10322162Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.Type: GrantFiled: January 6, 2016Date of Patent: June 18, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ECOLE NATIONALE VETERINAIRE D'ALFORT (ENVA)Inventors: Stéphane Germain, Alain Berdeaux, Renaud Tissier, Bijan Ghaleh-Marzban, Catherine Monnot, Ariane Galaup
-
Patent number: 10144975Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: GrantFiled: April 19, 2013Date of Patent: December 4, 2018Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Patent number: 9403880Abstract: The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.Type: GrantFiled: November 25, 2011Date of Patent: August 2, 2016Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUESTInventors: Marc Eloit, Justine Cheval, Virginie Sauvage
-
Patent number: 9228173Abstract: The present invention relates to isolated organ-specific feline endothelial cells. Specifically, the present invention relates to established organ-specific feline endothelial cells. The present invention also relates to organ-specific feline endothelial cells derived from micro- and macro-vascularisation. The present invention also relates to methods for screening molecules, for studying pathologies and for producing pathogens using same.Type: GrantFiled: January 11, 2011Date of Patent: January 5, 2016Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Claudine Kieda, Maria Paprocka, Michele Mitterand, Nathalie Lamerant-Fayel, Henri-Jean Boulouis, Nadia Haddad, Martine Monteil
-
Patent number: 9201076Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.Type: GrantFiled: December 28, 2012Date of Patent: December 1, 2015Assignees: Institut Pasteur, Ecole Nationale Veterinaire D'Alfort, Institut Curie, Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique (INRA)Inventors: Jean-Jacques Panthier, Giorgia Egidy, Xavier Sastre-Garau, Florence Bernex
-
Publication number: 20130345400Abstract: The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.Type: ApplicationFiled: November 25, 2011Publication date: December 26, 2013Applicants: INSTITUT PASTEUR, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Marc Eloit, Justine Cheval, Virginie Sauvage, Vincent Foulongne
-
Patent number: 8367348Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.Type: GrantFiled: July 28, 2008Date of Patent: February 5, 2013Assignees: Institut Pasteur, Institut Curie, Centre National de la Recherche Scientifique, Ecole Nationale Veterinaire d'Alfort, Institut National de la Recherche AgronomiqueInventors: Jean-Jacques Panthier, Giorgia Egidy, Xavier Sastre-Garau, Florence Bernex
-
Publication number: 20130017547Abstract: The present invention relates to isolated organ-specific feline endothelial cells. Specifically, the present invention relates to established organ-specific feline endothelial cells. The present invention also relates to organ-specific feline endothelial cells derived from micro- and macro-vascularisation. The present invention also relates to methods for screening molecules, for studying pathologies and for producing pathogens using same.Type: ApplicationFiled: January 11, 2011Publication date: January 17, 2013Applicants: ECOLE NATIONALE VETERINAIRE D'ALFORT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE - CNRSInventors: Claudine Kieda, Maria Paprocka, Michele Mitterand, Nathalie Lamerant-Fayel, Henri-Jean Boulouis, Nadia Haddad, Martine Monteil
-
Patent number: 8247182Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.Type: GrantFiled: July 6, 2010Date of Patent: August 21, 2012Assignees: Institut Pasteur, Institut Curie, Centre National de la Recherche Scientifique, Ecole Nationale Veterinaire d'Alfort, Institut National de la Recherche AgronomiqueInventors: Jean-Jacques Panthier, Giorgia Egidy, Xavier Sastre-Garau, Florence Bernex
-
Patent number: 8119396Abstract: Recombinant adenoviruses or pseudoviruses having a deletion of all or part of the region of the adenovirus genome corresponding to nucleotides 311 to 499 in canine adenovirus type 2 (GeneBank J04368). Therapeutic methods of using the recombinant adenovirus or pseudovirus.Type: GrantFiled: October 8, 2003Date of Patent: February 21, 2012Assignees: Institut National de la Recherche Agronomique (INRA), Ecole Nationale Veterinaire d'AlfortInventors: Marc Eloit, Bernard Klonjkowski
-
Publication number: 20100297632Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.Type: ApplicationFiled: July 28, 2008Publication date: November 25, 2010Applicants: Institut Pasteur, Centre National de la Recherche Scientifique, Institut Curie, Ecole Nationale Veterinaire D'Alfort, Institut Nat'l de la Recherche Agronomique (Inra)Inventors: Jean-Jacques Panthier, Giorgia Egidy, Xavier Sastre-Garau, Florence Bernex